Journal of Alzheimer's Disease (JAD)

The Journal of Alzheimer’s Disease (JAD) is a high-impact, peer-reviewed medical and scientific journal established in 1998 and dedicated to publishing authoritative research on Alzheimer’s disease and related neurodegenerative conditions. With a bimonthly publication frequency (24 issues per year), JAD provides a consistent forum for original research reports, comprehensive reviews, short communications, hypotheses, and scholarly analyses that explore mechanisms of disease, clinical characterization, biomarkers, genetics, and therapeutic strategies. The journal’s interdisciplinary reach brings together contributions from basic scientists, clinicians, epidemiologists, behavioral researchers, and healthcare professionals, fostering integrated understanding of Alzheimer’s disease from molecular pathology to patient outcomes. Research published in JAD covers key areas including neurobiology of Alzheimer’s, biomarker discovery, cognitive and behavioral studies, genetic risk factors, neuroimaging advances, pharmacological and non-pharmacological interventions, and ethical dimensions of research and care. The journal’s global editorial board ensures rigorous peer review and academic excellence, making it a respected resource for researchers, clinicians, and policymakers striving to improve diagnosis, treatment, and quality of life for individuals affected by Alzheimer’s disease. As of 2025, the journal is transitioning publishing to SAGE Publications, maintaining its tradition of excellence under a leading scholarly publisher.

Journal of Alzheimer's Disease (JAD) is :-

• International, Peer-Reviewed, Open Access, Refereed, Geriatrics and Gerontology, Psychiatry and Mental health, Clinical Psychology, clinical trials, systematic reviews, hypotheses and theoretical contributions, short reports, ethical analyses, and book reviews that span basic science, translational research, clinical applications, molecular and cellular pathology, biomarkers and neuroimaging, genetics and epigenetics, neuroinflammation, cognitive and behavioral outcomes, treatment strategies, risk factors , Online or Print , Bi-Monthly Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1387-2877, E-ISSN: 1875-8908, Established: 1998, Impact Factor: 3.1
• Does Not Provide Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE